Glutathione (GSH) and GSH-related enzymes constitute the most important defense system that protects cells from free radical, radiotherapy, and chemotherapy attacks. In this study, we aim to explore the potential role and regulatory mechanism of the GSH redox cycle in drug resistance in glioblastoma multiforme (GBM) cells. We found that temozolomide (TMZ)-resistant glioma cells displayed lower levels of endogenous reactive oxygen species and higher levels of total antioxidant capacity and GSH than sensitive cells. Moreover, the expression of glutathione reductase (GSR), the key enzyme of the GSH redox cycle, was higher in TMZ-resistant cells than in sensitive cells. Furthermore, silencing GSR in drug-resistant cells improved the sensitivity of cells to TMZ or cisplatin. Conversely, the over-expression of GSR in sensitive cells resulted in resistance to chemotherapy. In addition, the GSR enzyme partially prevented the oxidative stress caused by pro-oxidant Lbuthionine -sulfoximine. The modulation of redox state by GSH or L-buthionine -sulfoximine regulated GSR-mediated drug resistance, suggesting that the action of GSR in drug resistance is associated with the modulation of redox homeostasis. Intriguingly, a trend toward shorter progress-free survival was observed among GBM patients with high GSR expression. These results indicated that GSR is involved in mediating drug resistance and is a potential target for improving GBM treatment.
Glioblastoma multiforme (GBM), the most aggressive type of brain tumor, is highly proliferative, invasive, and difficult to completely resect through surgery (Furnari et al. 2007) . Its median survival time is only approximately 14 months (Hamilton et al. 2014) . Although many chemotherapeutic drugs, such as temozolomide (TMZ), nitrosoureas, and cisplatin, exert antitumor activities in patients with GBM, the efficacy of these drugs remains unsatisfactory because of the intrinsic and acquired resistance (Weller et al. 2013 (Weller et al. , 2014 . Therefore, exploring new strategies to reverse drug resistance and to improve the efficacy and prognosis of GBM have become an attractive field to neuro-oncologists (Kuczynski et al. 2013) .
Tumor heterogeneity causes differences in the sensitivity of tumor cells to therapeutic agents. Several studies have reported that the over-expression of efflux transporters, such as P-glycoprotein, multi-drug resistance-associated protein, and lung resistance-associated protein (Massey et al. 2014) , enhanced DNA repair and anti-apoptotic activity, metabolism reprogramming, abnormal microvasculature, and microenvironments, contribute to drug resistance (Holohan et al. 2013; Rebucci and Michiels 2013) . The underlying mechanisms of drug resistance, however, are multifactorial and poorly understood. It has been suggested that drug resistance in cancer cells is closely related to the redox status (Kuo 2009; Simons et al. 2009; Maiti 2012a) . Reactive oxygen species (ROS) is a significant indicator of intracellular redox homeostasis. As a first-line DNA-alkylating agent, TMZ kills glioma cells via elevated ROS; antioxidants inhibit TMZ-induced cytotoxicity (Lin et al. 2012) , suggesting that basal ROS levels and redox status in glioma cells play an important role in drug response (Maiti 2012a,b) .
The high rate of oxygen metabolism is found in neurons and astrocytes of human brain, where a large quantity of redox reactions occur. Under normal circumstances, oxidation and antioxidant systems are in a favorable state of dynamic equilibrium. Glutathione (GSH) and GSH-related enzymes in brain tissues constitute the most important antioxidant defense system that protects cells from free radical, radiotherapy, and chemotherapy attacks (Traverso et al. 2013) . Previous studies have reported that intracellular GSH levels are highly correlated with drug resistance. Increased GSH levels in human ovarian cancer cells induce the resistance of tumor cells to platinum (Belotte et al. 2013) , whereas decreased GSH levels in human multiple myeloma cells increase the sensitivity of tumor cells to arsenic trioxide (Srivastava et al. 2013) . Therefore, the GSH content of glioma cells is closely related to the overall regulation of redox status and drug response of cells (Backos et al. 2014) .
Glutathione S-transferases catalyze the GSH-dependent detoxification of various chemotherapeutic drugs. Several novel drugs that target glutathione S-transferases are currently being evaluated in clinical trials (Montero and Jassem 2011; . However, the role of the GSH redox metabolic cycle in cancer drug resistance has received minimal attention. Glutathione peroxidase (Gpx1) and glutathione reductase (GSR) are the two key enzymes that are involved in the redox metabolic cycle of GSH. Gpx1, which is found in the cytoplasm and mitochondria of eukaryotic cells, is one of the most important free radicaltrapping enzymes in the human body. Gpx1 oxidizes GSH (reduced form) to GSSG (oxidized form), whereas H 2 O 2 is reduced to H 2 O. GSSG is reduced by GSR, which uses NADPH as the reducing factor (Jefferies et al. 2003) . Thus, the GSH redox system is coupled with intracellular redox and energy metabolism balances via free thiol/disulfide bonds and NADPH/NADP + exchange, thus maintaining intracellular redox and energy metabolism homeostasis. Previous studies have revealed that Gpx1 regulates the sensitivity of glioma cells to oxidative stimuli (Dokic et al. 2012) . The GSR inhibitor was originally developed as an anti-malaria drug because it reduces GSH content and increases drug sensitivity (C ß akmak et al. 2011) . Therefore, we hypothesized that the GSH redox metabolic cycle is involved in maintaining the GSH content of the glioma cells, redox homeostasis, and regulating drug responsiveness.
In this study, we aim to further explore the regulatory mechanism of the GSH redox cycle in the drug resistance of GBM, and to provide new ideas and strategies to reverse drug resistance.
Materials and methods

Cell culture
Human GBM cell lines LN229 (RRID: CVCL_0393), U251 (RRID: CVCL_0021), LN18 (RRID: CVCL_0392) and T98G (RRID: CVCL_0556) were obtained from the American Type Culture Collection (Manassas, VA, USA). HEK 293T cells (RRID: CVCL_0045) were obtained from the Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China. These cells were grown in Dulbecco's modified Eagle's medium culture medium (Invitrogen, Carlsbad, CA, USA) that was supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 lg/ mL streptomycin in a humidified atmosphere with 5% CO 2 at 37°C.
MTT cell viability assay GBM cells were seeded in 96-well culture plates at a density of 1~3 9 10 3 cells/well. After 24 h, various concentrations of TMZ (Sigma, St. Louis, MO, USA), cisplatin (Hansoh Pharmaceutical Co., Ltd, Jiangsu, China), or dimethyl sulfoxide (DMSO) (Solarbio Bioscience & Technology Co., Ltd, Beijing, China) were added to the cells. Following the indicated time periods for incubation, 5 mg/ mL MTT (Sigma) was added into each well for 4 h. The supernatants were carefully aspirated, and formazan crystals were dissolved, using DMSO. Absorbance was recorded at 570 nm using a microplate reader.
Colonogenic survival assay
For colonogenic survival studies, 300 cells were seeded in 12-well plates and then exposed to different treatments for 48 h. After 10-14 days of incubation, the colonies were fixed for 6 min in cold methanol and then stained with 1% crystal violet solution for 30 min. Colonies of more than 50 cells were counted. Percent colony formation was calculated by assigning the untreated cultures as 100%. The percent colony formation of the treated cells was determined as: colony formation of treated cells/colony formation of untreated cells 9 100.
Plasmid construction, lentivirus packaging, and stable cell line generation PLKO.1-puro lentiviral vector was used to express human GSRspecific shRNAs for GSR knockdown. A scrambled sequence that does not target any known human coding sequence was used as the negative control. The upstream sequence for GSR shRNA is: CCGGCGCCTGAATGCCATCTATCAACTCGAGTTGATAGAT GGCATTCAGGCGTTTTT. The downstream sequence for GSR shRNA is: AATTAAAAACGCCTGAATGCCATCTATCAACTC-GAGTTGATAGATGGCATTCAGGCG. For stable transfection with GSR, human GSR cDNA was cloned into the pCDH-CMV-MCS-EF1-Puro lentiviral vector for lentivirus production. Lentiviral vectors were co-transfected with two packaging plasmids into 293T cells via the DNA-calcium phosphate precipitation method. GBM cells were infected with the lentiviral vector and selected using 2 lg/mL G418 (Sigma) at 48 h after 2 weeks of viral infection.
Knockdown or over-expression was validated by Western blot analysis and quantitative real-time PCR (qPCR).
Western blot analysis
Cells were washed with ice-cold phosphate-buffered saline (PBS) (Solarbio Bioscience & Technology Co.) and lysed in sodium dodecyl sulfate lysis buffer (Beyotime Biotechnology, Jiangsu, China). Protein concentration was quantified by bicinchoninic acid reagent (Pierce, Rockford, IL, USA), and 30 lg lysates were separated by sodium dodecyl sulfate -polyacrylamide gel electrophoresis and then electrotransferred onto polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). The membranes were blocked with 5% nonfat milk and incubated with primary antibodies overnight at 4°C. After washing, the membranes were incubated with IRDye-conjugated anti-rabbit or anti-mouse IgG antibodies (LI-COR Biosciences Inc., Lincoln, NE, USA). The proteins were then visualized with an Odyssey LI-COR infrared imaging system. Rabbit monoclonal antibodies against O 6 -methylguanine-DNA methyltransferase (MGMT; RRID: AB_776338) were purchased from Abcam (Cambridge, MA, USA) and Gpx1 (RRID: AB_10694353) were purchased from Cell Signaling Technology (Danvers, MA, USA). Mouse monoclonal antibodies against GSR (RRID: AB_2295121) and b-actin (RRID: AB_2714189) were purchased from Santa Cruz Inc. (Santa Cruz, CA, USA). IRDye-conjugated anti-rabbit or anti-mouse IgG antibodies were obtained from LI-COR Biosciences Inc.
Measurement of intracellular ROS by flow cytometry
Intracellular hydrogen peroxide was detected with a 2 0 ,7 0 -dichlorofluorescin diacetate (DCFH-DA) fluorescent probe (Beyotime Biotechnology). Cells were cultured in six-well plates and treated as indicated. Cells were washed twice with PBS and then incubated with 5 lM DCFH-DA at 37°C for 30 min. The 2 0 ,7 0 -dichlorofluorescein (DCF) fluorescence of 10 000 cells per sample was measured using the FACS Canto II flow cytometer (BD Biosciences, San Jose, CA, USA) with excitation and emission settings at 488 and 530, respectively. The mean fluorescent intensity in each treatment group was normalized by the mean fluorescent intensity of the control group of each cell line. The ratios were then expressed as the total ROS level.
Determination of intracellular GSH, total antioxidant capacity, and GSR activity The levels of intracellular GSH, total antioxidant capacity, and GSR activity were determined, using assay kits (Beyotime Biotechnology) in accordance with the manufacturer's instructions. For GSH content analysis, subconfluent cells were washed twice with PBS, harvested with a cell scraper, and centrifuged at 100 9g for 5 min. Cells were resuspended in protein removal reagent and were vigorously vortexed. The samples were subjected to two freeze-thaw cycles. The supernatant was subsequently collected by centrifugation at 10 000 9g for 10 min. The levels of intracellular GSH were determined using an assay kit. For the GSR activity analysis, the cells were washed twice with PBS and lysed in Triton X-100 lysis buffer. GSR activity was measured on the basis of NADPH consumption using a spectrophotometer at 340 nm in accordance with the manufacturer's instructions. For the analysis of total antioxidant capacity, cells were harvested through scraping and were broken by ultrasonic vibration on ice. The supernatant was collected by centrifugation at 10 000 9g and 4°C for 10 min. The total antioxidant capacity of the cell extracts was measured on the basis of 2,2 0 -Azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid substrate color reaction using an assay kit in accordance with the manufacturer's instructions. Results were expressed as Trolox equivalent antioxidant capacity based on the Trolox standard curve.
RNA extraction and real-time RT-PCR Cells were plated onto a 10-cm culture dish and grown to semiconfluency. RNA was isolated using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer's instructions. Two micrograms of RNA per sample were converted to cDNA, using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, USA). Relative gene expression was quantified using CFX96 real-time PCR (Bio-Rad Laboratories, Hercules, CA, USA) with a SYBR-Green kit (Kapa, Woburn, MA, USA) that enables the real-time detection of PCR products following the manufacturer's protocol. The cDNA was submitted for real-time PCR analysis, using the primer pairs as given below. The PCR primers were synthesized by GENEWIZ, Inc. (Jiangsu, China). The cycling conditions were as follows: 40 cycles of 95°C for 3 min, 95°C for 3 s, 60°C for 25 s, and 60°C for 5 min. The relative amount of target mRNA was calculated via the 2 ÀMMCt method.
Each sample was analyzed with b-actin as the endogenous reference gene for mRNA normalization. The primer sequences were as follows: GSR forward: TGGCACTTGCGTGAATGTTG, reverse: CACATAGGCATCCCGCTTTTC; b-actin forward: TCCCTGGA-GAAGAGCTACG, reverse: GTAGTTTCGTGGATGCCACA.
Xenograft in vivo
Female BALB/c (RRID: IMSR_HAR:1255) nude mice (four weeks old) were purchased from the Academy of Military Medical Sciences (Beijing, China). The animals were maintained under standardized environmental conditions: 22-28°C, 60-70% relative humidity, 12/12 h dark/light cycle, and water ad libitum. Cells (3 9 10 6 /mouse) were subcutaneously injected into the left hind flank of each mouse. Tumor volume was calculated using the formula V = (a9b 2 )/2, where a is the tumor length and b is the tumor width. When the tumor volumes reached 100 mm 3 , the mice were randomized to treatment or vehicle groups (5 mice per group). TMZ was administered via intraperitoneal (i.p.) injection at a dose of 50 mg/kg in 10% DMSO in saline daily for 5 consecutive days. Tumor growth was monitored and measured twice a week with a vernier caliper. Tumors were removed from mice at 21 days after treatment. The relative tumor volume (RTV) was calculated as the ratio between the tumor volume at time t and the tumor volume at the start of treatment. Inhibition rates were expressed as TRTV/ CRTV% (RTV of the treatment groups versus RTV of the control group) by dividing the RTVs of the treatment groups by those of the control group, and then multiplying the quotient by 100. All protocols were approved by the Institutional Review Board of Tianjin Medical University Cancer Institute and Hospital.
Tissue samples and immunohistochemistry (IHC) analysis
This experiment was performed in accordance with the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of Tianjin Medical University. GSR expression in the formalin-fixed and parrffin-embedded specimens from patients who were diagnosed with primary GBM [WHO grade IV (Louis et al. 2016) ] were analyzed using an immunohistochemistry (IHC) kit (ZSGB-BIO, Beijing, China)in accordance with the manufacturer's instructions. The intensity of staining was scored as 1 = low; 2 = medium; and 3 = high. The extent of staining was scored as 1 = 0-25% stained; 2 = 25-75% stained; and 3 = 75-100% stained. The final score was determined by multiplying the scores of intensity with the extent of staining; the value ranges from 0 to 9. Final scores of 1-2 were considered as low staining and 4-9 as high staining.
Statistical analysis
Randomization was performed with a computer-generated sequence of random numbers in the xenograft experiment, but other experiments were not. No sample calculation or blinding was performed. No mice were excluded from the analysis.
Data are presented as means AE standard deviation from three independent experiments. All data were analyzed by GraphPad Prism 5.01. Mean values were compared using unpaired Student's t-test or ANOVA with Bonferroni's multiple comparison test. Normality distribution was performed by Shapiro-Wilk test. A Spearman rank correlation coefficient test was carried out for testing the association between GSR expression and demographic variables. Kaplan-Meier models were applied to illustrate survival curves. The log-rank test was used to analyze the differences between groups. Statistical significance was represented as p < 0.05 (*) or p < 0.01 (**).
Results
GSR expression in GBM cells is correlated with TMZ and cispatin resistance
The GSR and MGMT statuses of 4 human GBM cell lines were assessed via Western blot analysis. MGMT protein was expressed in T98G and LN18 cells (MGMT + ) but not in LN229 and U251 cells (MGMT À ). Interestingly, T98G and LN18 cells expressed high levels of GSR (GSR high ), whereas LN229 and U251 expressed low levels of GSR (GSR low ) (Fig. 1a) . A similar trend was observed for GSR expression at the mRNA level (Fig. 1b and c) . By contrast, no significant trend was found for Gpx1 expression either at the protein or mRNA level.
The response of GBM cell lines to TMZ was analyzed with metabolic MTT analysis. Cells were treated with various concentrations of TMZ for 7 days. As shown in Fig. 1d , TMZ inhibited the viability of the four glioma cell lines in a dose-dependent manner. Moreover, GSR low / MGMT À LN229 and U251 cells were more sensitive to TMZ (IC 50 was 47.6 and 86.3 lg/mL, respectively), whereas GSR high /MGMT + T98G and LN18 cells were resistant to TMZ (IC 50 values exceeded 200 lg/mL). Similar results were observed with these cells after cisplatin exposure (Fig. 1e) . Thus, GSR expression and resistance to TMZ and cispatin in the survival assays are highly correlated.
TMZ-resistant glioma cells exhibit low levels of ROS and high levels of GSH and total antioxidant capacity We measured the levels of intracellular ROS, GSH, and total antioxidant capacity as indices of redox homeostasis in TMZ-resistant and -sensitive cells. First, the changes in total ROS production were estimated by DCFH-DA, a cellpermeable probe that is non-fluorescent when chemically reduced but fluoresces after cellular oxidation and the removal of acetate groups by cellular esterases. As shown in Fig. 2a (Fig. 2b and c) . These results indicated that the levels of intracellular ROS, GSH, and total antioxidant capacity are closely related to responsiveness to TMZ treatment. Thus, cells with intrinsically lower levels of oxidative stress might overcome attacks by therapeutic agents that that further increase oxidative stress. These cells are more resistant to drugs than the cells with elevated levels of oxidative stress.
GSR knockdown resensitizes GSR
high /MGMT + cells to TMZ and cisplatin To prove the pivotal role of GSR in mediating TMZ or cisplatin resistance, LN18 and T98G was used to establish a GSR-silenced cell line. GSR levels in LN18 and T98G cells with silenced GSR expression (designated as LN18/ shGSR and T98G/shGSR, respectively) were verified by western blotting at the protein level and by quantitative real-time PCR at the mRNA level ( Fig. 3a and b, Fig. S1a  and b) . GSR knockdown did not affect the expression of MGMT repair protein (Fig. 3a, Fig. S1a ). Then, we used these cell lines to assess the effect of GSR on cell growth by observing proliferation curve in vitro. As shown in Fig. 3c and Fig. S1c , GSR knockdown significantly reduced the proliferation of GBM cells. There was no significant difference in protein expression levels of GSR, mRNA expression levels of GSR, and the proliferation rate between the scramble group and the wildtype (wt) group.
Treatment with TMZ or cisplatin alone induced a response in LN18/shGSR (Fig. 3d and e) and T98G/shGSR cells ( Fig. S1d and e) comparable to that in scramble cells. In addition, the clonogenic capacities of LN18/shGSR (Fig. 3f  and g ) and T98G/shGSR ( Fig. S1f and g ) cells markedly decreased after exposure to TMZ or cisplatin alone.
GSR over-expression mediates TMZ and cisplatin resistance Then, we examined whether GSR over-expression regulates the responsiveness of therapeutic agents. LN229 and U251 cells were used to establish the GSR-over-expressing cell lines. GSR levels in LN229 and U251 cells with forced GSR expression (designated as LN229/GSR and U251/GSR, respectively) were verified by western blotting at the protein level and by quantitative real-time PCR at the mRNA level ( Fig. 4a and b, Fig. S2a and b) . Over-expression of GSR resulted in higher proliferation as detected by growth curves Cells were washed twice with phosphate-buffered saline (PBS) and harvested with a cell scraper. The samples were subjected to two freeze-thaw cycles, and the supernatant was collected via centrifugation at 10 000 9g for 10 min. The levels of intracellular GSH were determined, using an assay kit. (c) Cells were harvested by scraping and were lysed by ultrasonic vibration. The supernatant was collected by centrifugation at 10 000 9g and 4°C for 10 min. The total antioxidant capacity of cell extracts was measured using an assay kit as described in the Materials and Methods section. ANOVA test was used to analyze statistical significance; *p < 0.05, **p < 0.01.
than those in vector control cells (designated as LN229/vc and U251/vc, respectively) (Fig. 3c, Fig. S2c) . Moreover, the numbers of colonies significantly increased in GSR overexpression cells following incubation with TMZ or cisplatin ( Fig. 4d-g, Fig. S2d-g ).
GSR regulates GSH levels and BSO-mediated ROS production
To elucidate the underlying mechanisms of GSR-mediated resistance, we assessed the effect of GSR levels on GSR activity and GSH level. Both LN18/shGSR and T98G/ shGSR cells exhibited a significant decrease in GSR activity and total GSH content ( Fig. 5a and b, Fig. S3a and b) . By contrast, GSR activity and GSH content significantly increased in LN229/GSR ( Fig. 5d and e) and U251/GSR cells ( Fig. S3d and e) , indicating that the GSR enzyme regulates intracellular redox homeostasis and promotes switching to the redox state (GSH). We tested cellular response to additional external oxidative stress by treating cells with BSO (an inhibitor of GSH biosynthesis) for 24 h and subsequently determining the total ROS level by DCFH-DA. We found that the basal ROS in LN18 and T98G cells was increased because of GSR knockdown although no significant difference was observed (Fig. 5c, Fig. S3c ). By contrast, the basal ROS in LN229 and U251 cells was reduced by GSR over-expression (Fig. 5f, Fig. S3f ). Furthermore, exposure to BSO induced a significantly higher ROS level in GSR knockdown cells than in scramble cells (Fig. 5c, Fig. S3c) ; however, ROS level was dramatically lower in GSR-over-expressing cells than in vc cells (Fig. 5f, Fig. S3f ). These results suggested that the GSR enzyme partly prevents oxidative stress caused by prooxidants.
GSR mediates drug resistance by regulating GSH level and redox homeostasis
We further investigated the effect of GSH and redox state on the resistance of transfected cells to chemotherapeutic agents. GSH and redox state in cells were adjusted, using GSH and BSO. Interestingly, GSH attenuated the sensitivity of Ln18/ shGSR ( Fig. 6a and b ) and T98G/shGSR ( Fig. S4a and b) to TMZ and cisplatin. However, BSO reversed the resistance of LN229/GSR ( Fig. 6c and d ) and U251/GSR ( Fig. S4c and d) to these agents. These results suggested that the involvement of GSR in drug resistance resulted from its role in redox state balance. Therefore, GSR controls redox homeostasis, which in turn modulates the sensitivity of GBM cells to chemotherapeutic agents. 
Knockdown of GSR enhances the efficacy of TMZ in glioma xenografts
We assessed the effect of GSR on xenograft growth in vivo.
As shown in Fig. 7a , GSR knockdown significantly reduced the growth of xenograft tumors. The results were consistent with the in vitro data. Then we conducted an antitumor study using this mouse xenograft model to determine the effect of TMZ on tumor growth. Experimental outline was shown in Fig. 7b . The inhibition rates for LN18/scramble and LN18/ shGSR xenografts were 10.57 and 50.51%, respectively ( Fig. 7c and d) . These results suggest that knockdown of GSR can resensitize TMZ-resistant GBM cells to TMZ.
High levels of GSR expression is associated with an unfavorable progress-free survival (PFS) in GBM patients To examine the effect of GSR on drug response in vivo, the IHC analysis of GSR expression was conducted with 34 primary surgical specimens from GBM patients. The relationship between GSR expression and demographic variables was shown in Table 1 . There was no correlation of treatment, sex or age with GSR expression (p > 0.05).
Formalin-fixed and parrffin-embedded section with low and high GSR expression were shown in Fig. 8a and b, respectively. Kaplan-Meier models were used to illustrate progress-free survival (PFS) curves. The median PFS of patients with low GSR expression (n = 18) was 14 months, whereas that of patients with high GSR expression was 11 months (n = 16) (Fig. 8c) . Although some comparable differences were observed in median PFS, the results should be interpreted with caution because of the small sample size. In addition, the GSR expressions of primary and relapsed tumors from three GBM patients were compared through IHC staining. Two specimens of relapsed GBM showed significantly higher GSR expression levels than the counterpart primary tumors (data not shown).
Discussion
Malignant gliomas are the most aggressive type of primary brain tumors in adults (Holland 2000) . Current therapeutic strategies include surgery resection, radiotherapy, and adjuvant chemotherapy with TMZ, chloroethylating nitrosoureas, or cisplatin (Weller et al. 2013 ). However, many GBM patients fail to benefit from chemotherapy because of intrinsic and acquired resistances (Haar et al. 2012) . Several molecular mechanisms that underlie the resistance to these drugs have been described. Previous studies have reported that MGMT and p53 status mediate resistance to alkylating agents (Johannessen and Bjerkvig 2012) , and that cisplatin resistance is associated with increased drug-efflux, elevated DNA repair capacity, and higher GSH content (Byun et al. 2005; Galluzzi et al. 2012) . However, the mechanisms of resistance are complicated and remain poorly understood.
Thus, searching for an alternative treatment method and improving existing treatment strategies for GBM are urgent and necessary.
Most cancer cells are metabolically active and produce high levels of ROS; hence, these cells are vulnerable to further oxidative stress by exogenous ROS-generating agents (Pelicano et al. 2004) . TMZ and cisplatin are used to treat recurrent GBM; these drugs induce DNA damage and ROS production in gliomas, thus causing cell death (Itoh et al. 2011; Oliva et al. 2011; Yuan et al. 2012; Shi et al. 2015) . However, prolonged treatment with these drugs reduces ROS content in cancer cells and induces drug resistance (Maiti 2012b) . GSH is the most important small-molecule active oligopeptide in the maintenance of redox homeostasis (Townsend et al. 2003) . GSH contributes to antioxidant and thiol equilibrium and modulates the activities of numerous signaling molecules and redox-sensitive transcription factors through S-glutathionylation . Several studies have shown that GSH levels increase in various tumor types (Balendiran et al. 2004) , and that increased GSH is a major contributing factor to drug resistance via the elimination of ROS, detoxification of drugs, or participation in DNA repair processes (Fojo and Bates 2003) . GSH-related metabolic enzymes are overexpressed in resistant cells and regulate cell response to chemotherapy drugs (Tew 1994) . The depletion of GSH or down-regulation of GSH-related metabolic enzymes effectively reverses drug resistance and promotes the restoration of drug sensitivity in resistant cells. Thus, the GSH antioxidant system plays an important role in drug resistance. The GSH antioxidant system has recently become an attractive focus in cancer research given its potential as a target for antitumor therapy and drug resistance reversal (Fojo and Bates 2003; Backos et al. 2012) . Previous studies have reported that low ROS production is involved in the chemoresistance of gliomas to TMZ. The interference in cellular redox balance with pro-oxidant and GSH inhibitor potentiates TMZ cytotoxicity. Similarly, the GSH inhibitor reduces cisplatin resistance via GSH depletion (Rocha et al. 2014) . In this study, we observed that TMZ-resistant glioma cells showed lower ROS levels and higher total antioxidant capacity and GSH concentration than sensitive cells. These findings suggested that the resistant cells develop a strong antioxidant capacity to avoid drug attack. The reduced ROS content is a reason for the intrinsic and acquired drug resistances in malignant tumors (Maiti 2012b) . It has been suggested that high level of the GSH content TMZ cytotoxicity is mainly derived from DNA O 6 -G methylation in guanine-rich regions, whereas MGMT removes methyl groups from the O 6 position of guanine and potentiates TMZ resistance (Zhang et al. 2012) . Although TMZ is standard treatment for GBM patients, especially for those with methylated MGMT promoters (MGMT À ) (Hegi et al. 2005) , there is no appropriate option for patients with unmethylated MGMT promoters (MGMT + ). Our data revealed that the expression of GSR, a key enzyme in the GSH redox cycle, was higher in resistant cells (MGMT + ) than in sensitive cells (MGMT À ). We also revealed that GSR low / MGMT À cells are sensitive to TMZ, whereas GSR high / MGMT + cells are highly resistant to TMZ. The coexpression of GSR and MGMT in resistant cells indicate their potential correlation. However, MGMT expression was unaffected by the over-expression or down-regulation of GSR. This finding suggests that GSR and MGMT expression represent different mediatory mechanisms for chemoresistance in GBM cells. In addition, the over-expression or down-regulation of GSR induced protection against or sensitization to pro-oxidant therapeutic agents (TMZ and cisplatin). The modulation of redox state by GSH or BSO regulated GSR-mediated drug resistance. The results showed that GSR mediates drug resistance in GBM cells by regulating redox homeostasis. Reducing antioxidant capability in cancer cells by interfering with GSR is an effective approach to improving chemotherapeutic effect. Moreover, GSR is a predictor of treatment response because patients with high GSR expression showed poor PFS compared with patients with low GSR expression. It has been suggested that high levels of the GSH content in Plasmodium falciparum results in resistance to antimalarial agents. GSR inhibitors were discovered to fight against malaria (C ß akmak et al. 2011), and may become potential therapeutic agents for the treatment of cancer.
In conclusion, GSR might play a pivotal role in mediating drug resistance by regulating redox homeostasis, and targeting GSR in GBM enhances the efficacy of currently used chemotherapeutic agents. All experiments were conducted in compliance with the ARRIVE guidelines.
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